ClinicalTrials.gov
ClinicalTrials.gov Menu

Alpha-GPC and Physical and Cognitive Performances in Volleyball Players. (VolleyAGPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02886130
Recruitment Status : Completed
First Posted : September 1, 2016
Last Update Posted : April 21, 2017
Sponsor:
Information provided by (Responsible Party):
Raynald Bergeron, Université de Montréal

August 24, 2016
September 1, 2016
April 21, 2017
August 29, 2016
December 20, 2016   (Final data collection date for primary outcome measure)
Change in countermovement jump performance at 4 weeks [ Time Frame: Assessments at week 0 and at week 4 of supplementation or placebo ]
Jump height is calculated using two forces plates which measures the time the feet are off the platform. The athlete stands upright with weight evenly distributed over both feet. Hands are placed on the hips, and stay there throughout the test. When all is ready, the athlete squats down until the knees are bent at 90 degrees, then immediately jumps vertically as high as possible, landing back on the platform on both feet at the same time. Allow a good rest between trials. The take-off must be from both feet, with no initial steps or shuffling. They must also not pause at the base of the squat.
Same as current
Complete list of historical versions of study NCT02886130 on ClinicalTrials.gov Archive Site
  • Change in vertical jump - run up at 4 weeks [ Time Frame: Assessments at week 0 and at week 4 of supplementation or placebo ]
    Record the standing height of the subject by getting then to stand directly below the apparatus with both feet on tip-toes, and then stretch up one arm and reach as high as possible. The subject then stands the appropriate distance from the base of the apparatus (about 15 feet), and when ready take 3 or so steps before leaping off up off both legs as high as possible, using the arms to assist in projecting the body upwards. The subject should aim to take off just short of the apparatus, so that at the peak of the jump they are directly under it.
  • Executive function [ Time Frame: After 4 weeks of supplementation or placebo ]
    "Task switching" is a useful tool to investigate executive functions in humans. This task allows investigation of the ability to maintain, select and switch among task sets.
Same as current
Not Provided
Not Provided
 
Alpha-GPC and Physical and Cognitive Performances in Volleyball Players.
Effects of Alpha-glycerylphosphorylcholine on Physical and Cognitive Performances in Varsity Volleyball Players

In order to attain the elite level on the national scene, volleyball players need several attributes. In addition to mastering technical and tactical skills, great jumping ability is another important asset. Maximal power output needed to achieve height during a jump necessitates coordinated neuromuscular recruitment and muscle mass among others. Interestingly, there are claims that alpha-glycerylphosphorylcholine (A-GPC) increases acetylcholine synthesis and enhances exercise-induced increases in plasma growth hormone concentrations, two factors that could theoretically be associated neuromuscular transmission and muscle mass.

However, until now only a few studies have investigated the role of A-GPC in human exercise performance. Published results were mixed. One recent study showed that isometric peak force was slightly but significantly increased when subjects had ingested a daily dose of 600 mg of A-GPC over a period of 6 days (Bellar et al., JISSN, 2015).

The objective of our study is to evaluate the longer-term effects (4 weeks) using a higher dose (1000 mg/day) of A-GPC on jumping capabilities in elite male and female volleyball players.

Our study design will be a placebo controlled, randomized, double-blind, crossover study. Varsity male and female volleyball players (n=28) will each be asked to participate in both arms of the study, i.e. placebo and A-GPC (1000 mg/kg/day). The duration of each arm of the study will be 4 weeks separated by a 7-day washout period. The order of treatment (placebo or A-GPC) will be determined randomly. Athletes will be asked to maintain their training load during the duration of the experiment.
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Basic Science
Athletic Performance
  • Dietary Supplement: Placebo
    Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
    Other Names:
    • Maltodextrin
    • Control
  • Dietary Supplement: Experimental
    Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
    Other Names:
    • Alpha-gpc
    • Alpha-glycerylphosphorylcholine
    • Alpha-gpc supplementation
    • A-GPC
  • Placebo Comparator: Placebo
    Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
    Intervention: Dietary Supplement: Placebo
  • Experimental: Alpha-GPC
    Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
    Intervention: Dietary Supplement: Experimental

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
Same as current
December 20, 2016
December 20, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Be a competitive varsity volleyball player

Exclusion Criteria:

  • Regular consumption of alpha-GPC within the last 4 months
  • Receiving drug treatment except 1) contraception (pill), and 2) treatment against asthma
Sexes Eligible for Study: All
19 Years to 30 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT02886130
Montreal
No
Not Provided
Plan to Share IPD: Yes
Plan Description: Individual data obtained from vertical jump assessments and during the cognitive switch task will be communicated to each athlete.
Raynald Bergeron, Université de Montréal
Université de Montréal
Not Provided
Principal Investigator: Samuel St-Arnaud, B.Sc Université de Montréal
Study Director: Raynald Bergeron, Ph.D Université de Montréal
Study Director: Jonathan Tremblay, Ph.D Université de Montréal
Université de Montréal
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP